Health Technology Assessment

QALY measures have become important tools in valuing health interventions so that resource allocations can be made. Current methods, however, may not adequately capture QALYs for cancer patients, particularly in the last years of life. This post reviews the issues and suggests next steps.

Willingness-to-Pay for a New Pharmaceutical: Is it Worth the Money?  Whose  Money?

During this OHE Lunchtime Seminar, Prof Peter Zweifel,...

The EuroQol Group's 27th Scientific Plenary will take place in mid-September. Researchers will report on several exciting developments in the EQ-5D, a measure of self-reported health widely used in research and in the NHS PROMs programme. Professor Nancy Devlin (OHE) and Professor Jan van Busschbach (Erasmus MC) are the joint Scientific Chairs.

HTAinSite is a unique resource that enables subscribers to quickly find relevant information on NICE technology appraisal (TA) decisions and the evidence used to support them. Launched in May 2009, the project is a collaboration involving the OHE, City University London and Abacus International.

Tensions between broad access to new medical technologies and efforts to contain health care costs are perennial. In recent years, this has become evident in the uncomfortable discontinuities that can occur between health technology assessment (HTA) and regulatory approval of medicines. In autumn 2009, OHE and the Institute for Regulatory Science at CMR International collaborated on a two-day workshop on the issues raised.

In an article in Health Economics, Prof Devlin and her co-authors demonstrate the promise of using Lead Time TTO to value health 'state worse than death'. They demonstrate the potential advantages of the approach and identify important next steps in developing the methodology.

The OHE has won a £325,000 grant from the UK Department of Health that focuses on developing a new health status index – the 5 level EQ-5D --that will capture smaller changes in health related quality of life.

In a recent OHE Briefing, five leading European experts in health economics provide a comprehensive international review of changes in health economic evaluation and the reasons for them. The authors express concern that the basis for health care decision making today has evolved away from the societal perspective of cost benefit analysis to the payer perspective of cost-effectiveness analysis.

Pages

Subscribe to RSS - Health Technology Assessment